May 2, 2024
VIA EDGAR SUBMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Tim Buchmiller
| Re: | Xilio Therapeutics, Inc. |
| Registration Statement on Form S-3 |
| Filed April 30, 2024 |
File No. 333-279015
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Xilio Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-279015), so that it may become effective at 4:00 p.m. Eastern time on May 6, 2024, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the U.S. Securities and Exchange Commission.
Very truly yours,
XILIO THERAPEUTICS, INC.
By:/s/ René Russo
René Russo
President and Chief Executive Officer